Cell and gene therapies are coming into their own. Within the last two years there have been five first-time regulatory approvals worldwide, and a handful – including Novartis AG’s Zolgensma (onasemnogene abeparvovec) and bluebird bio Inc.’s LentiGlobin (human beta-globin) – are currently being reviewed in the US and EU, respectively, and potentially on track for approvals later in 2019.
For those already on the market, novel payment mechanisms, such as installment plans tied to efficacy, have emerged, as manufacturers...